Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy may let some esophageal cancer patients keep their esophagus

NCT ID NCT07317609

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 19 times

Summary

This early-phase study is testing whether giving a combination of chemotherapy and immunotherapy before any surgery can shrink esophageal cancer enough to allow doctors to remove the tumor through a scope, preserving the esophagus. About 60 adults with a specific type of esophageal cancer will receive the treatment and then be re-evaluated. If the cancer responds well, they may avoid major surgery; if not, standard treatments like surgery or radiation are still options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Zhongshan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)